A Phase III, Open-Label, Multicenter, Randomized Study t

Project: Research project

Description

A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (ANTI-PD-L1 ANTIBODY)compared with Docetaxel in patients with non-small cell lung cancer after platinum failure
StatusActive
Effective start/end date11/20/1311/20/19

Funding

  • Genentech Inc.

Fingerprint

docetaxel
Platinum
Non-Small Cell Lung Carcinoma
Multicenter Studies
Safety
Antibodies
MPDL3280A